The global cystic fibrosis (CF) therapeutics market is expected to be valued at USD 13.9 billion with CAGR of 16.7% over the forecast period. Cystic fibrosis (CF) is a severe disease that causes overall damage to lungs, digestive systems and other organs in the body. In this state, CF affects the cells that are responsible for sweat, mucus digestive and fluid juices. These juices are normally thin and slippery but patients suffering from cystic fibrosis experience thick blockage in lungs and other organs, as this affects the cells that regulate digestive and fluid juices causing them to become an obstacle rather than carriers. The cells instead of acting as a lubricant become sticky and thick, thus blocking up lungs, pancreas and other organs in the body. Medically this disease is termed as mucoviscidosis.
Download Free Sample Report @ https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market/request-sample
The major driving factors of this market rely significantly on extensive R&D. As the ongoing R&D activities have boosted the CF therapeutics market and witnesses a lucrative growth in the upcoming years. The other driving factors like awareness for cystic fibrosis therapy, technological advancements in R&D attribute to the success of market growth. However, high costs of treatment and R&D, entangled pathophysiology, rising rate in genetic mutation are some factors that may cause to hinder the market growth. On the basis of therapeutics, the global market is segmented into pulmozyme, TOBI, kalydeco, Cayston, Arikace, Aeroquin and others.
Cystic Fibrosis Trans membrane Conductance Regulators (CFTR) modulators treat the root cause of disease rather than symptoms, resulting in improving the lives of patients. Kalydeco is the first CFTR modulator to enter the market and had a large impact on the value of market though it treated a small proportion of CF patients. Pricing will be premium for CFTR modulators due to the therapeutic benefits. Symptomatic therapies will continue to be a necessary part in conjunction with CFTR modules. Comparatively, the antibiotics segment is expected to gain second importance owing to the competitiveness and novel market entrants.
A multi-resistant superbug infection that can prove fatal for patients suffering from cystic fibrosis (CF) has spread globally and is becoming viral, according to the British researchers. Moreover, it has not only gone viral but is evolved and capable to jump from patient to patient, according Andres Floto, a Cambridge University professor. Adding further, he said that as the superbug has become resistant to various antibiotics; it is also difficult to treat it successfully. As a part of treatment infected patients may need more than a year of treatment with a combination of strong antibiotics and the ratio of cure is one in three.
The market is segmented on the basis of geography which includes North America, Europe, Asia-Pacific, Middle-east and Africa. The European region dominates the global market scenario and is considered as the most fertile market which is also followed by North America. Asia-pacific regions are considered to be the least important market owing to less prevalence of the disorder. The key players include Novartis International AG, Chiesi Farmaceutici SpA, Vertex Pharmaceuticals, Genentech, Inc., and Gilead Sciences, Inc. Vertex Pharmaceuticals is the developer of kalydeco and expected to be a key player in the global market.
Market Segmentation
Cystic Fibrosis Therapeutics Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
- Pancreatic enzyme supplements
- Mucolytics
- Bronchodilators
- CFTR modulators
Cystic Fibrosis Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)
- Oral drugs
- Inhaled drugs
Cystic Fibrosis Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- South Africa
Browse Full Research Report with TOC @ https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market
Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Cystic Fibrosis Therapeutics Market Variables, Trends & Scope
3.1. Market Segmentation
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Key Opportunities Prioritized
3.4. Industry Analysis - Porter's
Continued…
Get in Touch
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.
Contact Person:
Ryan Manuel
Research Support Specialist, USA
Email: [email protected]
Global Headquarters
Million Insights
Felton Office Plaza 6265 Highway 9 Felton, California 95018, United States
Phone: 1-408-610-2300
Email: [email protected]
Asia Pacific
Million Insights
Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016 India
Phone: 91-20-65300184
The global market consist of players such as AbbVie, Allergan plc, Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Novartis AG, Pharmaxis Ltd, PTC Therapeutics, and Vertex Pharmaceuticals Incorporated are some of the prominent players at the forefront of competition in the global cystic fibrosis market and are profiled in MRFR Analysis report.Cystic Fibrosis Market is expected to register a CAGR of 13.5% and is anticipated to reach USD 12,943.1 million by 2025Global Cystic Fibrosis Market - Overview:According to a recent study report published by the Market Research Future analysts, the global cystic fibrosis (CF) therapeutics market is growing at a double digit CAGR.
Currently there are approximately 1900 identified CFTR mutations that are responsible for the development of the disease condition.
CF being the rare disease, and due to the limited information available, the extensive research is required.
Global Cystic Fibrosis Market - Regional Analysis;Cystic fibrosis can occur in both genders as well as in all ethnic groups and races.
Cystic fibrosis is more common among the Caucasians.
However cystic fibrosis can also affect Latinos, American Indians, African, and Middle Eastern population.North America is one of the majorly affected region by the deadly disease cystic fibrosis.
Cystic fibrosis (CF) is a severe disease that causes overall damage to lungs, digestive systems and other organs in the body.
Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market/request-sample The key driving factors responsible for the growth of Cystic Fibrosis (CF) Therapeutics market : The major driving factors of this market rely significantly on extensive R As the ongoing R activities have boosted the CF therapeutics market and witnesses a lucrative growth in the upcoming years.
On the basis of therapeutics, the global market is segmented into pulmozyme, TOBI, kalydeco, Cayston, Arikace, Aeroquin and others.
Cystic Fibrosis Trans membrane Conductance Regulators (CFTR) modulators treat the root cause of disease rather than symptoms, resulting in improving the lives of patients.
Kalydeco is the first CFTR modulator to enter the market and had a large impact on the value of market though it treated a small proportion of CF patients.
Comparatively, the antibiotics segment is expected to gain second importance owing to the competitiveness and novel market entrants.
The global Cystic F0ibrosis (CF) Therapeutics Market is expected to be valued at USD 13.9 billion with CAGR of 16.7% over the forecast period.
Cystic fibrosis (CF) is a severe disease that causes overall damage to lungs, digestive systems and other organs in the body.
The major driving factors of this market rely significantly on extensive R As the ongoing R activities have boosted the CF therapeutics market and witnesses a lucrative growth in the upcoming years.
On the basis of therapeutics, the global market is segmented into pulmozyme, TOBI, kalydeco, Cayston, Arikace, Aeroquin and others.Cystic Fibrosis Trans membrane Conductance Regulators (CFTR) modulators treat the root cause of disease rather than symptoms, resulting in improving the lives of patients.
Kalydeco is the first CFTR modulator to enter the market and had a large impact on the value of market though it treated a small proportion of CF patients.
